SavedAdd your journal

Journals / Hitit Medical Journal / 2026 / Cilt: 8 Sayı: 1

Prognostic Significance of the Systemic Immune-Inflammation Index and Pan-Immune-Inflammation Value in Metastatic Soft Tissue Sarcoma

Metastatik Yumuşak Doku Sarkomunda Sistemik İmmün-İnflamasyon İndeksi ve Pan-İmmün-İnflamasyon Değerinin Prognostik Önemi

Mustafa Emre Duygulu(Erol Olçok Eğitim ve Araştırma Hastanesi)0000-0001-5113-6782
Elanur Karaman(Karadeniz Teknik Üniversitesi Tıp Fakültesi)0000-0002-4264-8214
Pages
1–8
Publication Date
2026-02-28
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion The SII and PIV indices can guide the determination of high-risk cases and poor prognostic groups in patients diagnosed with metastatic STS in clinical practice.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective Soft tissue sarcoma (STS) is a rare type of cancer that has many different histological subtypes.
📊
Key Findings & Data:Results The median value was calculated as 1019.6 for the SII and 586.0 for the PIV.
💡
Conclusion & Impact:Conclusion The SII and PIV indices can guide the determination of high-risk cases and poor prognostic groups in patients diagnosed with metastatic STS in clinical practice.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Pan-İmmün-İnflamasyon Değeri · Sarkom · Sistemik İmmün-İnflamasyon İndeksi.

Abstract

Objective Soft tissue sarcoma (STS) is a rare type of cancer that has many different histological subtypes. New prognostic markers are needed to predict the prognosis of patients with metastatic disease. We aimed to investigate the prognostic importance of the systemic immune-inflammation index (SII) and pan-immune-inflammation value (PIV) in patients diagnosed with metastatic STS. Material and Method A total of eighty-eight patients were evaluated retrospectively. The SII and PIV were calculated with the blood parameters that were checked before treatment. The Kaplan-Meier method was used for survival analysis. Results The median value was calculated as 1019.6 for the SII and 586.0 for the PIV. The median PFS was 7.1 months (95% CI 5.0–9.1) for PIV<586 patients and 4.1 months (95% CI 3.0–5.15) for PIV≥586 patients (p=0.007). The median OS was 20.7 months (95% CI 12.9–28.4) for PIV<586 patients and 10.7 months (95% CI 8.6–12.7) for PIV≥586 patients (p=0.001). The median PFS was 6.3 months (95% CI 3.3–9.2) for those with an SII<1019.6 and 4.3 months (95% CI 3.1–5.4) for those with an SII≥1019.6 (p=0.086). The median OS was 17.6 months (95% CI 11.1–24.2) for patients with an SII<1019.6 and 11.0 months (95% CI 10.1–11.9) for those with an SII≥1019.6 (p=0.005). In multivariate Cox regression analysis, PIV was found to be an independent prognostic factor for decreased OS (p=0.009). Conclusion The SII and PIV indices can guide the determination of high-risk cases and poor prognostic groups in patients diagnosed with metastatic STS in clinical practice.

Özet

Amaç Yumuşak doku sarkomları (YDS), çok sayıda histolojik alt grup içeren nadir bir kanser türüdür. Metastatik hastalıkta prognozu öngörebilmek için yeni belirteçlere ihtiyaç vardır. Çalışmamızda metastatik YDS tanılı hastalarda sistemik immün-inflamasyon indeksi (SII) ve pan-immün-inflamasyon değeri’nin (PIV) prognostik önemini araştırmayı amaçladık. Gereç ve Yöntem Toplamda seksen sekiz hasta retrospektif olarak değerlendirildi. Hastaların tedavi öncesi kan parametreleri ile SII ve PIV değerleri hesaplandı. Sağkalım analizleri için Kaplan-Meier yöntemi kullanıldı. Bulgular SII için medyan değer 1019.6, PIV için 586.0 olarak bulundu. Medyan progresyonsuz sağkalım (PFS), PIV<586 için 7.1 ay (%95 CI 5.4-9.8) ve PIV≥586 için 4.1 ay (%95 CI 3.2-5.5) olarak hesaplandı (p=0.007). Medyan genel sağkalım (OS) PIV<586 için 20.7 ay (%95 CI 13.9-30.5) ve PIV≥586 için 10.7 ay (%95 CI 9.2-13.7) olarak bulundu (p=0.001). Medyan PFS, SII<1019.6 için 6.3 ay (%95 CI 3.5-9.9) ve SII≥1019.6 için 4.3 ay (%95 CI 3.4-5.8) olarak hesaplandı (p=0.086). Medyan OS, SII<1019.6 için 17.6 ay (%95 CI 11.9-25.9) ve SII≥1019.6 için 11.0 ay (%95 CI 10.9-12.8) olarak bulundu (p=0.005). Çok değişkenli Cox regresyon analizinde PIV indeksinin düşük OS için bağımsız bir prognostik faktör olduğu saptandı, (p=0.009). Sonuç SII ve PIV indekslerinin metastatik YDS tanılı hastalarda yüksek riskli olguların ve kötü prognostik grupların belirlenmesinde, klinik pratikte yol gösterici olabileceği düşünüldü.

🔖

Cite This Article

Duygulu, M. E., Karaman, E. (2026). Prognostic Significance of the Systemic Immune-Inflammation Index and Pan-Immune-Inflammation Value in Metastatic Soft Tissue Sarcoma. Hitit Medical Journal, Cilt: 8 Sayı: 1, 1–8. https://doi.org/10.52827/hititmedj.1657483

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (21)

  1. Hui JY. Epidemiology and Etiology of Sarcomas. Surgical Clinics of North America 2016;96:901-914.
  2. Judson I, Verweij J, Gelderblom H, et al. European Organization and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomized controlled phase 3 trial. The Lancet Oncology 2014;15:415-423.
  3. Ramanathan RC, A'Hern R, Fisher C, Thomas JM. Modified staging system for extremity soft tissue sarcomas. Annals of Surgical Oncology 1999;6:57-69.
  4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;19:883-899.
  5. Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduction and Targeted Therapy 2021;6:263.
  6. Hu B, Yang XR, Xu Y, et al. Systemic immuneinflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Research 2014;20:6212-6222.
  7. Fucà G, Guarini V, Antoniotti C, et al. The Pan-ImmuneInflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. British Journal of Cancer 2020;123:403-409.
  8. Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine 2018;24:541-550.
  9. Christoffersson G, Vågesjö E, Vandooren J, et al. VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. Blood 2012;120:4653-4662.
  10. Timaxian C, Vogel CFA, Orcel C, et al. Pivotal Role for Cxcr2 in Regulating Tumor-Associated Neutrophil in Breast Cancer. Cancers (Basel) 2021;13:2584.
  11. Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. European Journal of Haematology 2021;14:173.
  12. Singh N, Baby D, Rajguru JP, et al. Thakkannavar SS, Pujari VB. Inflammation and cancer. Annals of African Medicine 2019;18:121-126.
  13. Nieswandt B, Hafner M, Echtenacher B, et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Research 1999;59:1295-1300.
  14. Queiroz KC, Shi K, Duitman J, et al. Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. International Journal of Cancer 2014;135:2294-2304.
  15. Ward Y, Lake R, Faraji F, et al. Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling that Coordinates Transendothelial Migration. Cell Reports 2018;23:808-822.
  16. Tian BW, Yang YF, Yang CC, et al. Systemic immuneinflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis. Immunotherapy 2022;14:1481-1496.
  17. Zhu M, Chen L, Kong X, et al. The Systemic ImmuneInflammation Index is an Independent Predictor of Survival in Breast Cancer Patients. Cancer Management and Research 2022;14:775-820.
  18. Qi X, Qiao B, Song T, et al. Clinical utility of the panimmune-inflammation value in breast cancer patients. Frontiers in Oncology 2023;13:1223786.
  19. Ma C, Yu R, Li J, et al. Preoperative prognostic nutritional index and systemic immune-inflammation index predict survival outcomes in osteosarcoma: A comparison between young and elderly patients. Journal of Surgical Oncology 2022;125:754-765.
  20. Chen L, Zeng H, Du Z, et al. Nomogram based on pretreatment inflammatory biomarkers predicting survival in patients with head and neck soft tissue sarcoma. Cancer Biomarkers 2020;291:151-161.
  21. Fausti V, De Vita A, Vanni S, et al. Systemic Inflammatory Indices in Second-Line Soft Tissue Sarcoma Patients: Focus on Lymphocyte/Monocyte Ratio and Trabectedin. Cancers (Basel) 2023;15:1080.